Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-05 |
2024-06 |
-0.19 |
N/A |
N/A |
N/A |
2024-05-07 |
2024-03 |
-0.28 |
-0.24 |
0.04 |
14.29% |
2024-02-27 |
2023-12 |
-0.37 |
-0.3 |
0.07 |
18.92% |
2023-11-06 |
2023-09 |
-0.48 |
-0.41 |
0.07 |
14.58% |
2023-08-07 |
2023-06 |
-0.45 |
-0.42 |
0.03 |
6.67% |
2023-05-08 |
2023-03 |
-0.44 |
-0.42 |
0.02 |
4.55% |
Date |
Firm |
Action |
From |
To |
2023-10-08 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-10-03 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-10-02 |
Evercore ISI Group |
Upgrade |
|
Outperform |
2023-09-18 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-09-18 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-09-13 |
Stifel |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-30 |
GOWEN MAXINE |
Director |
16.96K |
Conversion of Exercise of derivative security |
2024-05-30 |
HUMPHRIES WILLIAM DOUGLAS |
Director |
28.73K |
Conversion of Exercise of derivative security |
2024-06-17 |
LEONARD BRADEN MICHAEL |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2024-05-30 |
MEHRA ANAND |
Director |
43.36K |
Conversion of Exercise of derivative security |
2024-05-30 |
MILANO VINCENT J |
Director |
12.52K |
Conversion of Exercise of derivative security |
2024-05-30 |
MOLINEAUX CHRISTOPHER P |
Director |
53.16K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Wellington Management Group, LLP |
7.64M |
79.20M |
10.79% |
2023-06-29 |
Blackrock Inc. |
5.59M |
58.01M |
7.90% |
2023-06-29 |
RA Capital Management, L.P. |
4.40M |
45.61M |
6.21% |
2023-06-29 |
Rock Springs Capital Management, LP |
3.96M |
41.08M |
5.60% |
2023-06-29 |
Bain Capital Life Sciences Investors, LLC |
3.40M |
35.26M |
4.80% |
2023-06-29 |
BVF Inc. |
3.36M |
34.85M |
4.75% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.84M |
19.06M |
2.60% |
2023-08-30 |
iShares Russell 2000 ETF |
1.58M |
11.81M |
2.23% |
2023-06-29 |
Vanguard Extended Market Index Fund |
734.92K |
7.62M |
1.04% |
2023-07-30 |
Fidelity Small Cap Index Fund |
618.54K |
6.10M |
0.87% |
2023-08-30 |
iShares Russell 2000 Growth ETF |
574.98K |
4.30M |
0.81% |
2023-08-30 |
iShares NASDAQ Biotechnology ETF |
405.18K |
3.03M |
0.57% |